

Ontario Public Drug Programs

Drug Submission Status

Report for January 2016

Complete Streamlined Multiple-Source

Submissions for Off-Formulary Interchangeability

The Ministry of Health and Long-Term Care has received complete submissions for the following streamlined multiple-source drug products for Off-Formulary Interchangeability (OFI) designation. Subject to confirmation of Drug Identification Numbers (DIN) and prices by the manufacturers, as well as review and approval by the Executive Officer, these products may be designated as OFI drugs in a future Formulary update. Final OFI designation status will be communicated when the Formulary update is published on the Ministry website and via an OPDP Notice.

Manufacturer	Product	Reference Product	Generic Name	Strength	Dosage Form	DIN
Auro Pharma Inc.	Auro-Betahistine	Serc	betahistine HCl	8mg	tablet	02449145
Auro Pharma Inc.	Auro-Betahistine	Serc	betahistine HCl	16mg	tablet	02449153
Auro Pharma Inc.	Auro-Betahistine	Serc	betahistine HCl	24mg	tablet	02449161
Auro Pharma Inc.	Auro-Sildenafil	Viagra	sildenafil citrate	25mg	FC tablet	02414368
Auro Pharma Inc.	Auro-Sildenafil	Viagra	sildenafil citrate	50mg	FC tablet	02414376

Manufacturer	Product	Reference Product	Generic Name	Strength	Dosage Form	DIN
Auro Pharma Inc.	Auro-Sildenafil	Viagra	sildenafil citrate	100mg	FC tablet	02414384
Auro Pharma Inc.	Auro-Montelukast Chewable Tablet	Singulair	montelukast sodium	5mg	tablet	02422875
Auro Pharma Inc.	Auro-Tramadol/Acetaminophen	Tramacet	tramadol HCl/acetaminophen	37.5mg/325mg	FC tablet	02439050